The overall goal of the Gynecologic Cancer Specialized Program of Research Excellence (SPORE) at MD Anderson Cancer Center is to conduct highly innovative translational research for the prevention and treatment of uterine cancers. Encompassed within this overall goal are the following goals of the program: 1) to develop novel therapeutic strategies for advanced and recurrent endometrial cancer, 2) to promote novel strategies for chemoprevention of endometrial cancer in high risk cohorts, including obese women, and 3) to incorporate molecular diagnostics into clinical decision-making. Over the last 5 years, as the only Uterine Cancer SPORE, we established a highly productive uterine cancer translational research community that is unparalleled in breadth and depth. This Proposal includes 4 Projects that display high translational impact and outstanding scientific merit, led by experienced translational scientists. Project 1, """"""""Metformin for the Chemoprevention of Endometrial Cancer in Obese, Insulin-Resistant Women,"""""""" includes a chemoprevention trial using metformin for obese, insulin-resistant women. Project 2, """"""""Use of Endometrial Biomarkers for Prediction of Advanced Disease,"""""""" seeks to determine if a panel of molecular biomarkers discovered during the first five years of the SPORE can address a specific and important clinical dilemma facing surgeons caring for women with endometrial cancer. Project 3, """"""""EphA2 Targeting in Uterine Carcinoma,"""""""" focuses on a novel therapeutic target, EphA2. EphA2 is overexpressed in a substantial proportion of uterine cancers, is associated with poor overall survival, and has been shown to regulate angiogenesis. This project will include a phase Ib clinical trial of an immunoconjugate that links an anti-cancer therapeutic to an antibody against EphA2. Project 4 """"""""Targeting the PISK Signaling Pathway in Endometrial Carcinoma,"""""""" focuses on the role of the phosphatidylinositol-3-kinase PI3K/PTEN/AKT/mT0R signaling pathway in endometrial tumorigenesis. Preliminary data suggests that mutations exist in multiple nodes of this pathway, and that responsiveness to pathway inhibitors may differ based on mutation. This project will include a phase II clinical trial assessing the efficacy of the PI3K inhibitor, GSK2126458A, in advanced endometrial carcinoma. Four Cores will support these projects. Core A (Administrative Core), Core B (Pathology Core), Core C Biomarkers Core, and Core D (Biostatistics and Bioinformatics Core).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA098258-09
Application #
8521096
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (M1))
Program Officer
Kuzmin, Igor A
Project Start
2003-09-14
Project End
2015-08-31
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
9
Fiscal Year
2013
Total Cost
$1,418,231
Indirect Cost
$713,513
Name
University of Texas MD Anderson Cancer Center
Department
Other Health Professions
Type
Other Domestic Higher Education
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Pakish, Janelle B; Zhang, Qian; Chen, Zhongyuan et al. (2017) Immune Microenvironment in Microsatellite-Instable Endometrial Cancers: Hereditary or Sporadic Origin Matters. Clin Cancer Res 23:4473-4481
Zang, Yong; Yuan, Ying (2017) Optimal sequential enrichment designs for phase II clinical trials. Stat Med 36:54-66
Haemmerle, Monika; Taylor, Morgan L; Gutschner, Tony et al. (2017) Platelets reduce anoikis and promote metastasis by activating YAP1 signaling. Nat Commun 8:310
Noh, Kyunghee; Mangala, Lingegowda S; Han, Hee-Dong et al. (2017) Differential Effects of EGFL6 on Tumor versus Wound Angiogenesis. Cell Rep 21:2785-2795
Kurnit, Katherine C; Kim, Grace N; Fellman, Bryan M et al. (2017) CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence. Mod Pathol 30:1032-1041
Harjes, U; Bridges, E; Gharpure, K M et al. (2017) Antiangiogenic and tumour inhibitory effects of downregulating tumour endothelial FABP4. Oncogene 36:912-921
Suh, Han Na; Kim, Moon Jong; Jung, Youn-Sang et al. (2017) Quiescence Exit of Tert+ Stem Cells by Wnt/?-Catenin Is Indispensable for Intestinal Regeneration. Cell Rep 21:2571-2584
Soliman, Pamela T; Westin, Shannon N; Dioun, Shayan et al. (2017) A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer. Gynecol Oncol 146:234-239
Bruegl, Amanda S; Kernberg, Annessa; Broaddus, Russell R (2017) Importance of PCR-based Tumor Testing in the Evaluation of Lynch Syndrome-associated Endometrial Cancer. Adv Anat Pathol 24:372-378
Nagaraja, Archana S; Dood, Robert L; Armaiz-Pena, Guillermo et al. (2017) Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. JCI Insight 2:

Showing the most recent 10 out of 541 publications